المؤلفون: Patel, S.V., Jayaweera, D.T., Althoff, K.N., Eron, J.J., Radtchenko, J., Mills, A., Moyle, G., Santiago, S., Sax, P.E., Gillman, J., Mounzer, K., Elion, R.A., Huhn, G.D.

المصدر: PLoS ONE, 15(2)

مصطلحات موضوعية: ledipasvir plus sofosbuvir, elbasvir plus grazoprevir, alanine aminotransferase, aspartate aminotransferase, sofosbuvir, ribavirin, sofosbuvir plus velpatasvir, daclatasvir, peginterferon, dasabuvir plus ombitasvir plus paritaprevir plus ritonavir, simeprevir

العلاقة: https://doi.org/10.17615/5qhn-ad14Test; https://cdr.lib.unc.edu/downloads/6682x9962?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/6682x9962Test

الإتاحة: https://doi.org/10.17615/5qhn-ad14Test
https://cdr.lib.unc.edu/downloads/6682x9962?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/6682x9962Test

المؤلفون: Papatheodoridis G.V., Goulis J., Sypsa V., Lionis C., Manolakopoulos S., Elefsiniotis I., Anagnostou O., Tsoulas C., Hatzakis A., Dalekos G.N.

المصدر: Annals of Gastroenterology ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069701850&doi=10.20524%2faog.2019.0375&partnerID=40&md5=0b6c0c7afa7d41618fc15731d33befffTest

مصطلحات موضوعية: antivirus agent, elbasvir plus grazoprevir, glecaprevir plus pibrentasvir, ledipasvir plus sofosbuvir, nonstructural protein 5A inhibitor, ombitasvir plus paritaprevir plus ritonavir, ribavirin, sofosbuvir plus velpatasvir, sofosbuvir plus velpatasvir plus voxilaprevir, Article, beta thalassemia, chronic hepatitis C, disease elimination, disease severity, enzyme linked immunosorbent assay, follow up, general practitioner, genotype, Greece, hemoglobinopathy, Hepatitis C virus, high risk population, human, liver cirrhosis, liver disease, mass screening, morbidity, mortality, opiate substitution treatment, patient care

العلاقة: http://hdl.handle.net/11615/77861Test

الإتاحة: https://doi.org/10.20524/aog.2019.0375Test
http://hdl.handle.net/11615/77861Test

المؤلفون: C. Nwankwo, E. H. Elbasha, M. N. Robertson

المصدر: Alimentary Pharmacology & Therapeutics

مصطلحات موضوعية: Ledipasvir, Cyclopropanes, Liver Cirrhosis, Elbasvir, medicine.medical_specialty, Sofosbuvir, Genotype, Cost effectiveness, Cost-Benefit Analysis, Administration, Oral, Hepacivirus, Viral Nonstructural Proteins, Gastroenterology, Antiviral Agents, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Predictive Value of Tests, Internal medicine, Quinoxalines, Virology, Drug Resistance, Viral, Elbasvir, Grazoprevir, Medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Benzofurans, Sulfonamides, Polymorphism, Genetic, Hepatology, business.industry, Imidazoles, Hepatitis C, Chronic, Amides, Ombitasvir, United States, Elbasvir plus Grazoprevir for HCV, chemistry, Grazoprevir, Paritaprevir, 030211 gastroenterology & hepatology, Original Article, Drug Therapy, Combination, Carbamates, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddf17ea35381f09ce5b47a1945327150Test
http://europepmc.org/articles/PMC6680317Test

مصطلحات الفهرس: adult, Hepatitis C virus genotype 1, Hepatitis C virus genotype 4, Hepatitis C virus genotype 6, human, insomnia/si [Side Effect], intention to treat analysis, liver cirrhosis, male, rash/si [Side Effect], headache/si [Side Effect], retreatment, sustained virologic response, treatment duration, treatment outcome, relapse, hepatitis C/dt [Drug Therapy], article, clinical article, drug dose reduction, drug efficacy, drug safety, drug tolerability, drug withdrawal, fatigue/si [Side Effect], female, gastrointestinal symptom/si [Side Effect], elbasvir plus grazoprevir/ae [Adverse Drug Reaction], elbasvir plus grazoprevir/cb [Drug Combination], elbasvir plus grazoprevir/dt [Drug Therapy], nonstructural protein 5A/ec [Endogenous Compound], ribavirin/ae [Adverse Drug Reaction], ribavirin/cb [Drug Combination], ribavirin/dt [Drug Therapy], sofosbuvir/ae [Adverse Drug Reaction], sofosbuvir/cb [Drug Combination], sofosbuvir/dt [Drug Therapy], sofosbuvir plus velpatasvir/cb [Drug Combination], sofosbuvir plus velpatasvir/dt [Drug Therapy], adverse event, antiviral therapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35904Test
Liver International
Click here for full text options
LibKey Link

مصطلحات الفهرس: adult, Hepatitis C virus genotype 1, Hepatitis C virus genotype 4, Hepatitis C virus genotype 6, human, insomnia/si [Side Effect], intention to treat analysis, liver cirrhosis, male, rash/si [Side Effect], headache/si [Side Effect], retreatment, sustained virologic response, treatment duration, treatment outcome, relapse, hepatitis C/dt [Drug Therapy], article, clinical article, drug dose reduction, drug efficacy, drug safety, drug tolerability, drug withdrawal, fatigue/si [Side Effect], female, gastrointestinal symptom/si [Side Effect], elbasvir plus grazoprevir/ae [Adverse Drug Reaction], elbasvir plus grazoprevir/cb [Drug Combination], elbasvir plus grazoprevir/dt [Drug Therapy], nonstructural protein 5A/ec [Endogenous Compound], ribavirin/ae [Adverse Drug Reaction], ribavirin/cb [Drug Combination], ribavirin/dt [Drug Therapy], sofosbuvir/ae [Adverse Drug Reaction], sofosbuvir/cb [Drug Combination], sofosbuvir/dt [Drug Therapy], sofosbuvir plus velpatasvir/cb [Drug Combination], sofosbuvir plus velpatasvir/dt [Drug Therapy], adverse event, antiviral therapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35904Test
Liver International
LibKey Link

مصطلحات الفهرس: double blind procedure, drug therapy, fatigue, female, follow up, health survey, hemophilia A, hemophilia B, Hepatitis C virus genotype 1, human, major clinical study, male, mental health, nonhuman, pain, adult, quality of life, randomized controlled trial, sickle cell anemia, social interaction, visually impaired person, von Willebrand disease, elbasvir plus grazoprevir, placebo, conference abstract, beta thalassemia, phase 3 clinical trial, chronic hepatitis C, controlled study, Conference Abstract

URL: Click here for full text options
LibKey Link

مصطلحات الفهرس: double blind procedure, drug therapy, fatigue, female, follow up, health survey, hemophilia A, hemophilia B, Hepatitis C virus genotype 1, human, major clinical study, male, mental health, nonhuman, pain, adult, quality of life, randomized controlled trial, sickle cell anemia, social interaction, visually impaired person, von Willebrand disease, elbasvir plus grazoprevir, placebo, conference abstract, beta thalassemia, phase 3 clinical trial, chronic hepatitis C, controlled study, Conference Abstract

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38951Test
LibKey Link

مصطلحات الفهرس: male, medication compliance, multicenter study, nausea/si [Side Effect], open study, patient compliance, phase 2 clinical trial, priority journal, pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], retreatment, single drug dose, sustained virologic response, tachycardia/si [Side Effect], vomiting/si [Side Effect], elbasvir/cb [Drug Combination], elbasvir plus grazoprevir/dt [Drug Therapy], grazoprevir/ae [Adverse Drug Reaction], grazoprevir/ct [Clinical Trial], grazoprevir/cb [Drug Combination], grazoprevir/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], ledipasvir plus sofosbuvir/dt [Drug Therapy], ribavirin/ae [Adverse Drug Reaction], ribavirin/ct [Clinical Trial], ribavirin/cb [Drug Combination], ruzasvir/ae [Adverse Drug Reaction], ruzasvir/ct [Clinical Trial], ruzasvir/cb [Drug Combination], ruzasvir/dt [Drug Therapy], uprifosbuvir/ae [Adverse Drug Reaction], uprifosbuvir/ct [Clinical Trial], uprifosbuvir/cb [Drug Combination], uprifosbuvir/dt [Drug Therapy], virus RNA/ec [Endogenous Compound], Hepatitis C virus subtype 2c, monotherapy, adult, aged, antiviral therapy, article, combination drug therapy, controlled study, diarrhea/si [Side Effect], drug efficacy, drug safety, drug treatment failure, drug withdrawal, fatigue/si [Side Effect], female, follow up, headache/si [Side Effect], hemoglobin blood level, hepatitis C/dt [Drug Therapy], hepatitis C/et [Etiology], Hepatitis C virus, Hepatitis C virus genotype 1, Hepatitis C virus genotype 2, Hepatitis C virus genotype 3, Hepatitis C virus subtype 1a, Hepatitis C virus subtype 1b, Hepatitis C virus subtype 2a, Hepatitis C virus subtype 2b, Hepatitis C virus subtype 3a, Hepatitis C virus subtype 3b, human, insomnia/si [Side Effect], limit of quantitation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38586Test
Hepatology
Click here for full text options
LibKey Link

مصطلحات الفهرس: male, medication compliance, multicenter study, nausea/si [Side Effect], open study, patient compliance, phase 2 clinical trial, priority journal, pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], retreatment, single drug dose, sustained virologic response, tachycardia/si [Side Effect], vomiting/si [Side Effect], elbasvir/cb [Drug Combination], elbasvir plus grazoprevir/dt [Drug Therapy], grazoprevir/ae [Adverse Drug Reaction], grazoprevir/ct [Clinical Trial], grazoprevir/cb [Drug Combination], grazoprevir/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], ledipasvir plus sofosbuvir/dt [Drug Therapy], ribavirin/ae [Adverse Drug Reaction], ribavirin/ct [Clinical Trial], ribavirin/cb [Drug Combination], ruzasvir/ae [Adverse Drug Reaction], ruzasvir/ct [Clinical Trial], ruzasvir/cb [Drug Combination], ruzasvir/dt [Drug Therapy], uprifosbuvir/ae [Adverse Drug Reaction], uprifosbuvir/ct [Clinical Trial], uprifosbuvir/cb [Drug Combination], uprifosbuvir/dt [Drug Therapy], virus RNA/ec [Endogenous Compound], Hepatitis C virus subtype 2c, monotherapy, adult, aged, antiviral therapy, article, combination drug therapy, controlled study, diarrhea/si [Side Effect], drug efficacy, drug safety, drug treatment failure, drug withdrawal, fatigue/si [Side Effect], female, follow up, headache/si [Side Effect], hemoglobin blood level, hepatitis C/dt [Drug Therapy], hepatitis C/et [Etiology], Hepatitis C virus, Hepatitis C virus genotype 1, Hepatitis C virus genotype 2, Hepatitis C virus genotype 3, Hepatitis C virus subtype 1a, Hepatitis C virus subtype 1b, Hepatitis C virus subtype 2a, Hepatitis C virus subtype 2b, Hepatitis C virus subtype 3a, Hepatitis C virus subtype 3b, human, insomnia/si [Side Effect], limit of quantitation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38586Test
Hepatology
Click here for full text options
LibKey Link